Blueprint Medicines Says Data on BLU-554 Show 16% Objective Response Rate in Hepatocellular Carcinoma

Blueprint Medicines Says Data on BLU-554 Show 16% Objective Response Rate in Hepatocellular Carcinoma

Blueprint Medicines (BPMC) said Monday an ongoing phase 1 clinical trial of BLU-554 demonstrated a 16% objective response rate in patients with FGFR4-driven advanced hepatocellular carcinoma (HCC). In addition, 49% of patients with FGFR4-driven HCC had radiographic tumor reduction. The company said BLU-554 was well-tolerated and most adverse events reported by investigators were grade 1 or 2. Median progression free survival was 3.7 months among patients with FGFR4-driven HCC. The […]

Read More ˃